Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2016 Aug;38(6):409–417. doi: 10.1097/MPH.0000000000000589

TABLE 3.

Summary of Doses of Asparaginase Received per Phase for S-PEG and I-PEG Treatment Groups

S-PEG I-PEG
Reporting Period Starting RP Off Tx during RP Received 2 doses of PEG in RP Starting RP Off Tx during RP Received ≥ 4 doses of PEG in RP
Consolidation 54 0 41 30 12 18
IM 54 0 36 18 0 14
DI 54 1 34 18 3 11

RP: reporting period